Submitted:
29 July 2024
Posted:
31 July 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
2.1. Patients’ Characteristics
2.2. Comparison of Immune Phenotype between HD and HDF Patients
2.3. Effect of HFV
2.4. Effect of Vintage
2.5. Immune Phenotype May Be Related to Increased Mortality
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. Flow Cytometry
4.3. Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cohen, G. Immune Dysfunction in Uremia 2020. Toxins (Basel). 2020 Jul;12(7).
- Kramer A, Pippias M, Noordzij M, Stel VS, Andrusev AM, Aparicio-Madre MI, et al. The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary. Clin Kidney J. 2019 Oct;12(5):702–20.
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C yuan. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. New England Journal of Medicine. 2004;351(13):1296–305. [CrossRef]
- Vogelzang JL, van Stralen KJ, Noordzij M, Diez JA, Carrero JJ, Couchoud C, et al. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrol Dial Transplant. 2015 Jun;30(6):1028–37. [CrossRef]
- Lioulios G, Fylaktou A, Asouchidou D, Xochelli A, Nikolaidou V, Stai S, et al. Effect of Lymphocyte Phenotypic Alterations on the Humoral Response to Vaccination Against SARS-COV-2 in Dialysis Patients. Ann Lab Med. 2023 Sep 1;43(5):451–60. [CrossRef]
- Van Laecke S, Van Damme K, Dendooven A. Immunosenescence: an unexplored role in glomerulonephritis. Vol. 11, Clinical and Translational Immunology. John Wiley and Sons Inc; 2022. [CrossRef]
- Lioulios G, Fylaktou A, Papagianni A, Stangou M. T cell markers recount the course of immunosenescence in healthy individuals and chronic kidney disease. Clin Immunol. 2021 Apr;225:108685. [CrossRef]
- Sampani E, Stangou M, Daikidou DV, Nikolaidou V, Asouchidou D, Dimitriadis C, et al. Influence of end stage renal disease on CD28 expression and T-cell immunity. Nephrology. 2021 Feb 1;26(2):185–96. [CrossRef]
- Litjens NHR, van Druningen CJ, Betjes MGH. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006 Jan;118(1):83–91. [CrossRef]
- Yadav AK, Lal A, Jha V. Cytotoxic CD4+CD28null T lymphocytes, systemic inflammation and atherosclerotic risk in patients with chronic kidney disease. Nephron Clin Pract. 2012 Oct;120(4). [CrossRef]
- Ducloux D, Legendre M, Bamoulid J, Saas P, Courivaud C, Crepin T. End-Stage Renal Disease-Related Accelerated Immune Senescence: Is Rejuvenation of the Immune System a Therapeutic Goal? Vol. 8, Frontiers in Medicine. Frontiers Media S.A.; 2021.
- Losappio V, Franzin R, Infante B, Godeas G, Gesualdo L, Fersini A, et al. Molecular mechanisms of premature aging in hemodialysis: The complex interplay between innate and adaptive immune dysfunction. Vol. 21, International Journal of Molecular Sciences. MDPI AG; 2020. [CrossRef]
- Glorieux G, Gryp T, Perna A. Gut-derived metabolites and their role in immune dysfunction in chronic kidney disease. Vol. 12, Toxins. MDPI AG; 2020. [CrossRef]
- Blankestijn PJ, Fischer KI, Barth C, Cromm K, Canaud B, Davenport A, et al. Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: The comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol. BMJ Open. 2020 Feb 5;10(2). [CrossRef]
- Tattersall JE, Ward RA; EUDIAL group. Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant. 2013 Mar;28(3):542-50. [CrossRef] [PubMed]
- Lang T, Zawada AM, Theis L, Braun J, Ottillinger B, Kopperschmidt P, et al. Hemodiafiltration: Technical and Medical Insights. Bioengineering. 2023 Jan 21;10(2):145. [CrossRef]
- Susantitaphong P, Siribamrungwong M, Jaber BL. Convective therapies versus low-flux hemodialysis for chronic kidney failure: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2013 Nov;28(11):2859–74. [CrossRef]
- Vallejo AN, Bryl E, Klarskov K, Naylor S, Weyand CM, Goronzy JJ. Molecular basis for the loss of CD28 expression in senescent T cells. J Biol Chem. 2002 Dec;277(49):46940–9. [CrossRef]
- Chiu WK, Fann M, Weng N ping. Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines. J Immunol. 2006 Dec;177(11):7802–10. [CrossRef]
- Borthwick NJ, Lowdell M, Salmon M, Akbar AN. Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. Int Immunol. 2000 Jul;12(7):1005–13.
- Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity. 2008 Dec;29(6):848–62. [CrossRef]
- Meijers RW, Litjens NH, de Wit EA, Langerak AW, van der Spek A, Baan CC, et al. Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients. Immun Ageing. 2012 Sep;9(1):19. [CrossRef]
- Crépin T, Legendre M, Carron C, Vachey C, Courivaud C, Rebibou JM, et al. Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients. Nephrol Dial Transplant. 2020 Apr;35(4):624–32. [CrossRef]
- Zal B, Kaski JC, Arno G, Akiyu JP, Xu Q, Cole D, et al. Heat-Shock Protein 60-Reactive CD4+CD28null T Cells in Patients with Acute Coronary Syndromes. Circulation. 2004 Mar 16;109(10):1230–5.
- Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000 Jun;101(25):2883–8. [CrossRef]
- Liuzzo G, Kopecky SL, Frye RL, O’Fallon WM, Maseri A, Goronzy JJ, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation. 1999 Nov;100(21):2135–9. [CrossRef]
- Liuzzo G, Biasucci LM, Trotta G, Brugaletta S, Pinnelli M, Digianuario G, et al. Unusual CD4+CD28null T Lymphocytes and Recurrence of Acute Coronary Events. J Am Coll Cardiol. 2007 Oct 9;50(15):1450–8. [CrossRef]
- Nowik M, Nowacki P, Grabarek J, Drechsler H, Białecka M, Widecka K, et al. Can we talk about CD4+CD28- Lymphocytes as a risk factor for ischemic stroke? Eur Neurol. 2007 Jul;58(1):26–33.
- Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. Journal of Experimental Medicine. 2006 Jan 23;203(1):239–50. [CrossRef]
- Callender LA, Carroll EC, Beal RWJ, Chambers ES, Nourshargh S, Akbar AN, et al. Human CD8(+) EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. Aging Cell. 2018 Feb;17(1).
- Chiu YL, Shu KH, Yang FJ, Chou TY, Chen PM, Lay FY, et al. A comprehensive characterization of aggravated aging-related changes in T lymphocytes and monocytes in end-stage renal disease: The iESRD study. Immunity and Ageing. 2018 Nov 8;15(1). [CrossRef]
- Borges A, Borges M, Fernandes J, Nascimento H, Sameiro-Faria M, Miranda V, et al. Apoptosis of peripheral CD4++ T-lymphocytes in end-stage renal disease patients under hemodialysis and rhEPO therapies. Ren Fail. 2011;33(2):138–43. [CrossRef]
- Stefanidis I, Voliotis G, Papanikolaou V, Chronopoulou I, Eleftheriadis T, Kowald A, et al. Telomere Length in Peripheral Blood Mononuclear Cells of Patients on Chronic Hemodialysis Is Related With Telomerase Activity and Treatment Duration. Artif Organs. 2015 Sep 1;39(9):756–64. [CrossRef]
- Xiang F, Chen R, Cao X, Shen B, Chen X, Ding X, et al. Premature aging of circulating T cells predicts all-cause mortality in hemodialysis patients. BMC Nephrol. 2020 Jul 13;21(1). [CrossRef]
- Molina M, Allende LM, Ramos LE, Gutiérrez E, Pleguezuelo DE, Hernández ER, et al. CD19+ B-cells, a new biomarker of mortality in hemodialysis patients. Front Immunol. 2018 Jun 15;9(JUN). [CrossRef]
- Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. Front Immunol. 2020 Jul 22;11:1582. [CrossRef] [PubMed] [PubMed Central]
- Sampani E, Daikidou DV, Lioulios G, Xochelli A, Mitsoglou Z, Nikolaidou V. CD28null and Regulatory T Cells Are Substantially Disrupted in Patients with End-Stage Renal Disease Due to Diabetes Mellitus. Int J Mol Sci. 2021 Mar 15;22(6):2975. [CrossRef] [PubMed] [PubMed Central]
- Lioulios G, Fylaktou A, Xochelli A, Sampani E, Tsouchnikas I, Giamalis P, et al. Clustering of End Stage Renal Disease Patients by Dimensionality Reduction Algorithms According to Lymphocyte Senescence Markers [Internet]. Vol. 13, Frontiers in Immunology . 2022. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2022.841031.





| 20-40 | 41-60 | 61-80 | Total | |
|---|---|---|---|---|
| Ν | 21 | 21 | 20 | 62 |
| Mean age ± sd, years | 30.5 ± 6.3 | 52.2 ± 5.6 | 71.2 ± 6.4 | 51.3 ± 17.7 |
| Sex, male/female | 14/7 | 14/7 | 9/11 | 37/25 |
| Mean weight ± sd, kg | 61 ± 11.5 | 81.3 ± 19.2 | 71.1 ± 12.5 | 71.3 ± 17 |
| Mean BMI ± sd, kg/m2 | 21 ± 3.2 | 25.9 ± 3.9 | 25.5 ± 3.6 | 24.5 ± 4.1 |
| Cause of ESRD | ||||
| Primary glomerulonephritis (%) | 3(14.3) | 10(47.6) | 4(20) | 17(27.4) |
| Hypertension | 1(4.8) | 2(9.5) | 0(0) | 3(4.8) |
| Obstructive nephropathy | 5(23.8) | 1(4.8) | 2(10) | 8(12.9) |
| Polycystic kidney disease | 1(4.8) | 2(9.5) | 4(20) | 7(11.2) |
| Other | 6(28.6) | 1(4.8) | 1(5) | 7(11.2) |
| Unknown | 5(23.8) | 5(23.8) | 9(45) | 19(30.6) |
| Dialysis characteristics | ||||
| Classic hemodialysis | 11 | 9 | 16 | 36 |
| Online hemodiafiltration | 10 | 12 | 4 | 26 |
| Mean vintage ± sd, months | 45 ± 48 | 101 ± 81 | 67 ± 44 | 72 ± 64 |
| Kt/V ± sd | 1.29 ± 0.05 | 1.27 ± 0.06 | 1.23 ± 0.04 | 1.27 ± 0.07 |
| Mean dialysis duration ± sd, Min | 240 ± 14 | 246 ± 11 | 234 ± 13 | 240 ± 14 |
| Comorbidities | ||||
| Hypertension | 11 | 11 | 10 | 32 |
| Cardiovascular disease | 2 | 11 | 8 | 21 |
| Secondary hyperparathyroidism | 11 | 12 | 11 | 34 |
| Anemia | 18 | 15 | 18 | 51 |
| History of kidney transplantation (%) | 4(19) | 6(28.6) | 0(0) | 10(16.1) |
| Prior immunosuppression (%) | 5(23.8) | 11(52.3) | 3(15) | 19(30) |
| Median time since immunosuppression cessation(IQR), months | 75(43-148) | 45(36-63) | 48(-) | 48(40-96) |
| Laboratory values, median (IQR) | ||||
| Hemoglobin, g/dl | 11.6(10.8-11.9) | 11.2(10.4-11.7) | 10.5(10-11.1) | 11(10.5-11.6) |
| Urea, mg/dl | 130(96-149) | 145(117-154) | 121(112-140) | 127(110-149) |
| Creatinine, mg/dl | 9.7(7.8-11.8) | 9.1(7.1-10.9) | 8.4(5.8-9.5) | 9.1(7.1-10.8) |
| Calcium, mg/dl | 9.1(8.8-9.2) | 8.9(8.8-9.5) | 9.2(8.7-9.6) | 9.1(8.8-9.3) |
| Phosphorus, mg/dl | 4.6(4-5.5) | 4.6(3.3-5) | 4(3.8-4.5) | 4.4(3.8-5.1) |
| Parathormone, pg/ml | 162(89-391) | 268(145-376) | 197(98-244) | 206(106-353) |
| Albumin, g/dl | 4.3(3.9-4.4) | 4.2(3.9-4.3) | 3.9(3.8-4.1) | 4.1(3.9-4.3) |
| C reactive protein (mg/l) | 1.7(1.2-3.7) | 2.5(1.4-7.4) | 3.7(1.8-7.4) | 2.4(1.4-4.7) |
| Lymphocyte subsets (cells/μL) | Univariate Linear Regression | Multivariate Linear Regression | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hemofiltration volume | Hemofiltration volume | Age (years) | ||||||||
| B | R2 | 95% CI | P | PC | 95% CI | P | PC | 95% CI | P | |
| CD4+CD45RA-CCR7+ | 0.45 | 0.2 | 0.5, 10.8 | 0.03 | 0.33 | -1.1, 9.0 | 0.12 | -0.43 | -9.8, -0.2 | 0.04 |
| CD8+CD45RA-CCR7+ | 0.52 | 0.26 | 1.8, 13.1 | 0.01 | 0.48 | 1.1, 13.3 | 0.02 | -0.05 | -6, 5 | 0.81 |
| CD8+CD45RA+CCR7- | -0.49 | 0.24 | -3.2, -0.3 | 0.02 | -0.56 | -3.6, -0.6 | 0.006 | -0.32 | -2.4, 0.3 | 0.13 |
| CD19+ | 0.47 | 0.22 | 0.3, 4.5 | 0.02 | 0.36 | -0.3, 3.8 | 0.09 | -0.42 | -3.9, -0.03 | 0.04 |
| CD19+IgD+CD27- | 0.48 | 0.23 | 0.3, 3.2 | 0.02 | 0.38 | -0.2, 2.6 | 0.08 | 0.48 | -2.8, -0.2 | 0.02 |
| CD19+IgD-CD27+ | 0.45 | 0.20 | -0.05, 1.1 | 0.03 | 0.39 | 0.05, 1.1 | 0.07 | -0.16 | -0.7, 0.35 | 0.47 |
| CD19+IgD-CD27- | 0.12 | 0.01 | -0.3, 1.3 | 0.30 | -0.07 | -1.1, 0.8 | 0.75 | -0.11 | -1.2, 0.6 | 0.61 |
| Lymphocyte subsets (cells/μL) | Univariate Linear Regression | Multivariate Linear Regression | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Vintage (months) | Vintage (months) | Age (years) | ||||||||
| BC | R2 | 95% CI | P | PC | 95% CI | P | PC | 95% CI | P | |
| Total Lymphs | -0.21 | 0.04 | -3.6, 0.3 | 0.09 | -0.17 | -3.3, 0.6 | 0.18 | -0.16 | -12.0, 2.5 | 0.19 |
| CD4+ | -0.34 | 0.12 | -2.6, -0.4 | 0.006 | -0.30 | -2.3, -0.2 | 0.02 | -0.22 | -7.1, 0.4 | 0.08 |
| CD4+CD45RA+CD31+ | -0.31 | 0.98 | -0.9, -0.1 | 0.01 | -0.23 | -0.7, 0.02 | 0.06 | -0.46 | -3.9, -1.3 | <0.001 |
| CD4+CD45RA+CCR7+ | -0.38 | 0.15 | -1.6, -0.3 | 0.002 | -0.35 | -1.5, -0.2 | 0.006 | -0.17 | -3.8, 0.8 | 0.19 |
| CD4+CD45RA-CCR7+ | -0.17 | 0.03 | -1.2, 0.2 | 0.17 | -0.14 | -1.2, 0.3 | 0.26 | -0.11 | -4.0, 1.5 | 0.37 |
| CD8+CD45RA-CCR7+ | -0.13 | 0.02 | -1.2, -0.4 | 0.32 | -0.08 | -1.0, 0.5 | 0.53 | -0.20 | -5.3, 0.6 | 0.12 |
| CD19+ | -0.14 | 0.02 | -0.4, 0.1 | 0.28 | -0.01 | -0.2, 0.2 | 0.88 | -0.52 | -3.0, -1.2 | <0.001 |
| CD19+CD27+ | -0.22 | 0.05 | -0.2, 0.02 | 0.08 | -0.15 | -0.1, 0.04 | 0.22 | -0.29 | -0.8, -0.06 | 0.02 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).